Prognostic factors affecting long-term outcome after stem cell transplantation in Hodgkin's lymphoma autografted after a first relapseAnna Sureda, E. Condé, M. Constans et al.|Annals of Oncology|2005Cited by 220
Allogeneic stem cell transplantation after reduced intensity conditioning in patients with relapsed or refractory Hodgkin's lymphoma. Results of the HDR-ALLO study - a prospective clinical trial by the Grupo Espanol de Linfomas/Trasplante de Medula Osea (GEL/TAMO) and the Lymphoma Working Party of the European Group for Blood and Marrow TransplantationAnna Sureda, Norbert Schmitz, Carmen Canals et al.|Haematologica|2011Cited by 215
Thalidomide / Dexamethasone (TD) Vs. Bortezomib (Velcade)a/Thalidomide / Dexamethasone (VTD) Vs. VBMCP/VBAD/Velcadea as Induction Regimens Prior Autologous Stem Cell Transplantation (ASCT) in Multiple Myeloma (MM): Results of a Phase III PETHEMA/GEM Trial.Laura Rosiñol, Joan Bladé, M. Teresa Cibeira et al.|Blood|2009Cited by 45
Imipenem/cilastatin versus piperacillin/tazobactam plus amikacin for empirical therapy in febrile neutropenic patients: results of the COSTINE studyMiguel Á. Sanz, Arancha Bermúdez, Montserrat Rovira et al.|Current Medical Research and Opinion|2005Cited by 18